35 completed, 7 terminated, 4 withdrawn, 1 recruiting. 32 Phase 2, 12 Phase 1, 4 Not applicable, 1 Early Phase 1.
Follow Recurrent Adult Soft Tissue Sarcoma: new trials by email Literature Review of Recurrent Adult Soft Tissue Sarcoma trials Research Report on Recurrent Adult Soft Tissue Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SMMART Adaptive Clinical Treatment (ACT) Trial Alectinib, Alpelisib, Anastrozole - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Early Phase 1 | Withdrawn | OHSU Knight Cancer Institute | 2023-01-30 | 2024-01-23 | |
| Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma Durvalumab and Tremelimumab, Doxorubicin - Metastatic Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma | Phase 2 | Completed | AIO-Studien-gGmbH | 103 | 2017-12-15 | 2023-06-15 |
| Combination of Cryosurgery and NK Immunotherapy for Recurrent Sarcoma Cryosurgery, NK immunotherapy - Recurrent Adult Soft Tissue Sarcoma | Phase 1 / Phase 2 | Completed | Fuda Cancer Hospital, Guangzhou | 30 | 2016-07-01 | 2019-09-12 |
| Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort Conventional Surgery, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis - Recurrent Adult Soft Tissue Sarcoma | Not applicable | Recruiting | Jonsson Comprehensive Cancer Center | 51 | 2016-02-03 | 2026-03-10 |
| Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002) CMB305, atezolizumab - Sarcoma, Myxoid/Round Cell Liposarcoma | Phase 2 | Terminated | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 89 | 2015-04-29 | 2020-07-07 |
| Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas Pazopanib Hydrochloride, Oral Topotecan Hydrochloride, Laboratory Biomarker Analysis - Adult Liposarcoma, Metastatic Liposarcoma | Phase 2 | Completed | Northwestern University | 178 | 2015-03-21 | 2022-06-07 |
| NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Cyclophosphamide, Laboratory Biomarker Analysis - Adult Synovial Sarcoma, Myxoid/Round Cell Liposarcoma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2014-07-01 | 2016-02-03 | |
| Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma regorafenib - Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma | Phase 2 | Completed | Northwestern University | 31 | 2014-06-13 | 2022-04-25 |
| A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas tivozanib, laboratory biomarker analysis - Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma | Phase 2 | Completed | Northwestern University | 58 | 2013-03-06 | 2019-09-09 |
| Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Bevacizumab, Cetuximab, Laboratory Biomarker Analysis - Advanced Malignant Neoplasm, Castleman Disease | Phase 1 | Terminated | M.D. Anderson Cancer Center | 116 | 2012-10-16 | 2026-11-05 |
| Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Alisertib, Laboratory Biomarker Analysis - Myxofibrosarcoma, Recurrent Adult Soft Tissue Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 72 | 2012-08-22 | 2017-11-30 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Pharmacological Study, Romidepsin - Glioma, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 37 | 2012-08-03 | 2025-02-07 |
| Biomarkers in Patients With Advanced Rhabdomyosarcoma Laboratory Biomarker Analysis - Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma | Completed | Children's Oncology Group | 10 | 2012-08-01 | 2016-05-18 | |
| Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Trebananib - Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 16 | 2012-07-01 | 2015-10-19 |
| Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma isolated limb perfusion, melphalan, quality-of-life assessment - Basal Cell Carcinoma of the Skin, Eccrine Carcinoma of the Skin | Not applicable | Withdrawn | Albert Einstein College of Medicine | 2012-04-01 | 2015-07-23 | |
| Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma Gemcitabine, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma | Phase 2 | Completed | OHSU Knight Cancer Institute | 54 | 2012-03-13 | 2021-09-27 |
| Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery cyclophosphamide, NY-ESO-1-specific T cells, laboratory biomarker analysis - Adult Liposarcoma, Adult Synovial Sarcoma | Phase 1 | Completed | Fred Hutchinson Cancer Center | 6 | 2012-01-01 | 2014-12-11 |
| Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma pazopanib hydrochloride, laboratory biomarker analysis, positron emission tomography - Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma | Phase 2 | Completed | Fox Chase Cancer Center | 29 | 2011-11-03 | 2022-08-19 |
| Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases intensity-modulated radiation therapy - Adult Rhabdomyosarcoma, Lung Metastases | Not applicable | Completed | Ann & Robert H Lurie Children's Hospital of Chicago | 20 | 2011-02-01 | 2025-02-10 |
| Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma diagnostic laboratory biomarker analysis, everolimus, imatinib mesylate - Adult Synovial Sarcoma, Recurrent Adult Soft Tissue Sarcoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 14 | 2011-01-01 | 2014-10-08 |
Showing 20 of 47. Sign in to see all of them.
Sarcoma (47) · Rhabdomyosarcoma (12) · Sarcoma, Synovial (11) · Liposarcoma (10) · Hemangiosarcoma (8) · Osteosarcoma (8) · Histiocytoma, Malignant Fibrous (7) · Leiomyosarcoma (7) · Fibrosarcoma (6) · Neuroectodermal Tumors, Primitive, Peripheral (6) · Neurofibrosarcoma (6) · Dermatofibrosarcoma (5) · Gastrointestinal Stromal Tumors (5) · Chondrosarcoma, Extraskeletal Myxoid (4) · Desmoplastic Small Round Cell Tumor (4)
Neoplasms by Histologic Type (47) · Neoplasms, Connective and Soft Tissue (47) · Neoplasms (45) · Neoplasms, Connective Tissue (25) · Neoplasms, Muscle Tissue (14) · Neoplasms, Nerve Tissue (14) · Myosarcoma (12) · Neoplasms by Site (12) · Neoplasms, Adipose Tissue (11) · Neoplasms, Germ Cell and Embryonal (11) · Neoplasms, Glandular and Epithelial (11) · Neoplasms, Bone Tissue (10) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Neoplasms, Fibrous Tissue (9)
Doxorubicin (5) · Sirolimus (5) · temsirolimus (5) · Bevacizumab (3) · Cyclophosphamide (3) · Disulfides (3) · Filgrastim (3) · Immunoglobulin G (3) · Melphalan (3) · cixutumumab (3) · pazopanib (3) · Biopsy (2) · Fluorodeoxyglucose F18 (2) · Granulocyte Colony-Stimulating Factor (2) · HhAntag691 (2)
National Cancer Institute (NCI) (25) · Northwestern University (3) · Children's Oncology Group (2) · City of Hope Medical Center (2) · Fred Hutchinson Cancer Center (2) · OHSU Knight Cancer Institute (2) · AIO-Studien-gGmbH (1) · Albert Einstein College of Medicine (1) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Fox Chase Cancer Center (1) · Fuda Cancer Hospital, Guangzhou (1) · Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Jonsson Comprehensive Cancer Center (1) · M.D. Anderson Cancer Center (1) · National Institutes of Health Clinical Center (CC) (1)
United States (42) · Canada (7) · Australia (3) · New Zealand (2) · China (1) · Germany (1) · Netherlands (1) · Puerto Rico (1) · Switzerland (1)
Margaret von Mehren (2) · Scott Okuno (2) · Seth Pollack (2) · Warren Chow (2) · Anna Pawlowska, MD (1) · Anusa Kalbasi, MD (1) · Brenda Weigel, MD (1) · Brigitte Widemann (1) · Burton Eisenberg (1) · Charles Keller, MD (1) · Christopher W Ryan (1) · David D'Adamo (1) · David Walterhouse (1) · H. Richard Alexander, Jr. (1) · Howard Bailey (1)
PMID 31401903, PMID 22347360, PMID 23477833, PMID 25858498, PMID 26933802, PMID 27502708, PMID 27771610, PMID 31513481, PMID 34260265, PMID 37311055, PMID 39863139, PMID 41389341, PMID 41405883
P30CA008748 (4), N01CM17104 (3), U01CA069856 (3), U10CA098543 (3), N01CM00038 (2), N01CM00071 (2), N01CM62206 (2), P30CA015704 (2), P30CA060553 (2), U10CA031946 (2), U10CA180821 (2), 2016 (1), K23CA175167 (1), N01CM00032 (1), N01CM00100 (1)